North America Hereditary Cancer Testing Market to 2032
Overview
The North America Hereditary Cancer Testing Market is expected to reach a 8.13 USD Billion by 2032 and is projected to grow at a CAGR of 21.42% from 2025 to 2032.
Revenue, 2024 (USD Billion)
2.97
Forecast, 2032 (USD Billion)
8.13
CAGR, 2024 - 2032
21.42%
Report Coverage
North America
North America Hereditary Cancer Testing Market 2018-2032 USD Billion
North America Hereditary Cancer Testing Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 2.97 USD Billion
- Projected Market Size (2032): 8.13 USD Billion
- CAGR (2025-2032): 21.42%
Key Findings of North America Hereditary Cancer Testing Market
- The North America Hereditary Cancer Testing Market was valued at 2.97 USD Billion in 2024.
- The North America Hereditary Cancer Testing Market is likely to grow at a CAGR of 21.42% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Direct Tender in Distribution Channel Segment accounted for the largest share of the market with a revenue of 1.99 USD Billion
- The fastest growing segment Hospitals in End Users Segment grew Fastest with a CAGR of 22.47% during the forecast period from 2024 to 2032.
North America Hereditary Cancer Testing Market Scope
North America Hereditary Cancer Testing Market Segmentation & Scope
Disease
- Multiple Endocrine Neoplasias (MEN) Syndrome
- Von Hippel-Lindau Disease
- Li-Fraumeni Syndrome
- Familial Adenomatous Polyposis (FAP)
- Hereditary Leukemia and Hematologic Malignancies Syndrome
- Lynch Syndrome
- Cowden Syndrome
- Hereditary Breast & Ovarian Cancer Syndrome
Technology
- Microarray
- Sequencing
- Polymerase Chain Reaction (PCR)
Diagnosis
- Lab Tests
- Imagining
- Biopsy
Distribution Channel
- Retail Sales
- Direct Tender
End Users
- Others
- Laboratories
- Radiology Centres
- Diagnostics Centers
- Clinics
- Hospitals
Test
- Single Site Genetic Test
- Multi Panel Test
North America Hereditary Cancer Testing Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2020 |
| Unit | Revenue in USD Billion |
| Market Value in 2024 | 2.97 USD Billion |
| Market Value in 2032 | 8.13 USD Billion |
| CAGR (2025-2032) | 21.42% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Disease,Technology,Diagnosis,Distribution Channel,End Users,Test |
Regional Insights:
-
Leading Market (2024-2032): North America, leading in terms of revenue 2.97 USD Billion in 2024
- Key Country: U.S., leading in terms of revenue with value of 2,413.39 USD Million in 2024.
Segments and Scope
-
North America Hereditary Cancer Testing Market to 2032, By Disease
- Hereditary Breast & Ovarian Cancer Syndrome is the largest segment in North America Hereditary Cancer Testing Market to 2032 with a revenue of 1.63 USD Billion in the year 2024.
- Hereditary Breast & Ovarian Cancer Syndrome is the Fastest growing segment in North America Hereditary Cancer Testing Market to 2032 with a Growth rate of 22.16 % in forecast period 2025-2032.
-
North America Hereditary Cancer Testing Market to 2032, By Technology
- Polymerase Chain Reaction (PCR) is the largest segment in North America Hereditary Cancer Testing Market to 2032 with a revenue of 1.89 USD Billion in the year 2024.
- Polymerase Chain Reaction (PCR) is the Fastest growing segment in North America Hereditary Cancer Testing Market to 2032 with a Growth rate of 21.93 % in forecast period 2025-2032.
-
North America Hereditary Cancer Testing Market to 2032, By Diagnosis
- Biopsy is the largest segment in North America Hereditary Cancer Testing Market to 2032 with a revenue of 1.24 USD Billion in the year 2024.
- Biopsy is the Fastest growing segment in North America Hereditary Cancer Testing Market to 2032 with a Growth rate of 21.81 % in forecast period 2025-2032.
-
North America Hereditary Cancer Testing Market to 2032, By Distribution Channel
- Direct Tender is the largest segment in North America Hereditary Cancer Testing Market to 2032 with a revenue of 1.99 USD Billion in the year 2024.
- Direct Tender is the Fastest growing segment in North America Hereditary Cancer Testing Market to 2032 with a Growth rate of 21.61 % in forecast period 2025-2032.
-
North America Hereditary Cancer Testing Market to 2032, By End Users
- Hospitals is the largest segment in North America Hereditary Cancer Testing Market to 2032 with a revenue of 1.03 USD Billion in the year 2024.
- Hospitals is the Fastest growing segment in North America Hereditary Cancer Testing Market to 2032 with a Growth rate of 22.47 % in forecast period 2025-2032.
-
North America Hereditary Cancer Testing Market to 2032, By Test
- Multi Panel Test is the largest segment in North America Hereditary Cancer Testing Market to 2032 with a revenue of 1.93 USD Billion in the year 2024.
- Multi Panel Test is the Fastest growing segment in North America Hereditary Cancer Testing Market to 2032 with a Growth rate of 21.83 % in forecast period 2025-2032.
North America Hereditary Cancer Testing Market Company Share Analysis
| Company Name |
|
||
| PerkinElmer Inc. | |||
| illumina, inc. | |||
| Abbott | |||
| Eurofins Scientific | |||
| LifeLabs Genetics | |||
North America Hereditary Cancer Testing Market Geographical Sales Distribution, 2018-2032 USD Billion
North America Hereditary Cancer Testing Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The North America Hereditary Cancer Testing Market is segmented based on Segmentation Disease,Technology,Diagnosis,Distribution Channel,End Users,Test.
North America Hereditary Cancer Testing Market was valued at USD 2.97(Revenue in USD Billion) in 2020.
North America Hereditary Cancer Testing Market is projected to grow at a CAGR of 21.42% during the forecast period of 2024 to 2032.
The Direct Tender segment is expected to dominate the North America Hereditary Cancer Testing Market, holding a largest market share of 1.99 USD Billion in 2024
North America Hereditary Cancer Testing Market Scope
North America Hereditary Cancer Testing Market Segmentation & Scope
Disease
- Multiple Endocrine Neoplasias (MEN) Syndrome
- Von Hippel-Lindau Disease
- Li-Fraumeni Syndrome
- Familial Adenomatous Polyposis (FAP)
- Hereditary Leukemia and Hematologic Malignancies Syndrome
- Lynch Syndrome
- Cowden Syndrome
- Hereditary Breast & Ovarian Cancer Syndrome
Technology
- Microarray
- Sequencing
- Polymerase Chain Reaction (PCR)
Diagnosis
- Lab Tests
- Imagining
- Biopsy
Distribution Channel
- Retail Sales
- Direct Tender
End Users
- Others
- Laboratories
- Radiology Centres
- Diagnostics Centers
- Clinics
- Hospitals
Test
- Single Site Genetic Test
- Multi Panel Test
Frequently Asked Questions
The North America Hereditary Cancer Testing Market is segmented based on Segmentation Disease,Technology,Diagnosis,Distribution Channel,End Users,Test.
North America Hereditary Cancer Testing Market was valued at USD 2.97(Revenue in USD Billion) in 2020.
North America Hereditary Cancer Testing Market is projected to grow at a CAGR of 21.42% during the forecast period of 2024 to 2032.
The estimated market value of the North America Hereditary Cancer Testing Market for final year is USD 8.13 (USD Billion).
North America Hereditary Cancer Testing Market Company Profiling
Frequently Asked Questions
The North America Hereditary Cancer Testing Market is segmented based on Segmentation Disease,Technology,Diagnosis,Distribution Channel,End Users,Test.
North America Hereditary Cancer Testing Market was valued at USD 2.97(Revenue in USD Billion) in 2020.
North America Hereditary Cancer Testing Market is projected to grow at a CAGR of 21.42% during the forecast period of 2024 to 2032.
The estimated market value of the North America Hereditary Cancer Testing Market for final year is USD 8.13 (USD Billion).
CHOOSE LICENCE TYPE
- 4200.00
- 3500.00
- 2000.00
- 5500.00
- 8500.00
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.